• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

NO
     
IMMU (Immunomedics Inc)
Last Trade 19.07 Date 1/30/2020
Change % 3.98 % Price Change 0.73
Open 18.5 52 Week High 22.2206
High 19.29 52 Week Low 11.59
Low 18.41 Type stock
Volume 1030880 Average Volume 2248994
Prev Close 18.34 Stock Exchange NASDAQ
Bid 19.06 Ask 19.07
Bid Size 3 Ask Size 1
1st Yr Estimated EPS Growth 0.468 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.1147 Book Value Yield 0.0063
Buy Back Yield CAPE Ratio
Cash Return -0.0382 Cash Flow per Share -0.7676
Cash Flow Yield -0.0419 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0627 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 80.4879 EV / Pre Tax Income
EV / Revenue 2581.8784 EV / Total Asset 9.193
Expected Dividend Growth Rate Free Cash Flow per Share -0.8258
Free Caash Flow Ratio Free Cash Flow Yield -0.045
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0894 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 159.940115 PB Ratio 10 Year Growth 0.363961
PB Ratio 3 Year Growth 57.033005 Cash Ratio 3 Year Average 1136.2328
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 74.103125 PE Ratio 10 Year Growth
PE Ratio 10 Year High 367.0 PE Ratio 10 Year Low 5.836735
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.86673
Price to Cash Ratio 10.551081 Price / EBITDA
Price to Sales Ratio 2121.386995 Price to Sales Ratio 10 Year Growth 0.857973
Price to Sales Ratio 3 Year Avg 1173.028039 Price to Sales Ratio 5 Year Avg
Sale per Share 0.0069 Sales Yield 4.0E-4
Sustainable Growth Rate -1.5822 Tangible Book Value per Share 0.1147
Tangible Book Value per Share 3 year Avg 0.5023 Tangible Book Value per Share 5 year Avg 0.1265
Total Asset per Share 1.9384 Total Yield
Working Capital per Share 1.5067 Working Capital per Share 3 Year Avg 1.3573
Working Capital per Share 5 Year Avg 1.0174 Beta 1.314687